ClinicalTrials.gg
CompletedNCT00746317Updated Oct 17, 2012

A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

A Phase 1 interventional study of GC33 in Advanced or Metastatic HCC, sponsored by Chugai Pharmaceutical. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-17.

Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer.

Read the detailed description

This is a Phase I open-label dose escalation study of GC33 in patients with advanced or metastatic HCC. This study is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary assessment of anti-tumor activity. Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended Phase II dose has been established.

02

Conditions studied

  • Advanced or Metastatic HCC
03

In context

Lead sponsor

Chugai Pharmaceutical is the lead sponsor of 63 studies on the registry; 7 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written Institutional Review Board (IRB)/Ethical Committee (EC) approved form
  • Male or female ≥ 18 years old.
  • ≥ 3 months.
  • Performance Status of 0-1.
  • confirmed hepatocellular carcinoma (without fibrolamellar subtype).
  • Not a candidate for curative treatments.
  • A or B.
  • Hematological, Biochemical and Organ Function:

    • (SGOT): ≤ 5.0 ×
    • ALT (SGPT): ≤ 5.0 × ULN
    • Total : ≤ 3.0 × ULN
    • : ≥ 50,000/μL
    • : ≥ 1,500/μL
    • Serum creatinine: ≤ 2.0 × ULN
    • PT-: ≤ 2.0,
  • Ability to provide a tumor tissue sample either by:

    • a sample obtained within 3 months prior to informed consent for HCC diagnosis. Resection samples are not acceptable.
    • undergo a to confirm HCC diagnosis
  • At least one based on criteria.

(Extension Phase)

  • Signed written Institutional Review Board (IRB)/Ethical Committee (EC) approved informed consent form.
  • Male or female ≥ 18 years old.
  • Life expectancy ≥ 3 months.
  • ECOG Performance Status of 0-1.
  • Histologically confirmed hepatocellular carcinoma (without fibrolamellar subtype).
  • Not a candidate for curative treatments.
  • Child-Pugh A.
  • Hematological, Biochemical and Organ Function:

    • AST (SGOT): ≤ 5.0 × ULN
    • ALT (SGPT): ≤ 5.0 × ULN
    • Total Bilirubin: ≤ 3.0 × ULN
    • Platelets: ≥ 50,000/μL
    • Absolute Neutrophil Count: ≥ 1,500/μL
    • Serum creatinine: ≤ 2.0 × ULN
    • PT-INR: ≤ 2.0
  • IHC confirmed GPC3-positive HCC tumor tissue. Tumor tissue sample may be provided by:

    • A formalin fixed paraffin embedded block sample within 12 months prior to informed consent for HCC diagnosis;
    • Unstained slides obtained within 3 months prior to informed consent for HCC diagnosis;
    • Undergo biopsy to confirm GPC3-positive HCC.
    • Resection samples are not acceptable.
  • At least one measurable lesion based on Response Evaluation Criteria In Solid Tumors criteria.

Exclusion criteria

Exclusion Criteria:

  • C.
  • Pregnant or lactating women or women of and men of childbearing potential not willing to use effective means of .
  • Patients known to be positive for infection.
  • Active infectious diseases requiring treatment except for and C.
  • Other within the last 5 years.
  • History of transplantation (organ, bone marrow transplantation,peripheral blood stem cell transplantation, etc.).
  • Patients with significant concomitant disease determined by the investigator to be potentially aggravated by the drug.
  • Patients with , other central nervous system or other psychiatric disease.
  • Patients who received major surgery, local therapy for HCC, chemotherapy, radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4 weeks prior to Day 1.
  • Patients who received the following treatments within 2 weeks prior to Day1:

    • Anticoagulant or thrombolytic agents for therapeutic purposes.
    • Systemic anti-viral therapy for /cirrhosis.
    • Blood transfusion
  • History of to similar agents.
  • Patient is unable to comply with the requirements of the protocol and/or follow-up procedures.

(Extension Phase)

  • Child-Pugh B or C.
  • Pregnant or lactating women or women of child-bearing potential and men of childbearing potential not willing to use effective means of contraception.
  • Patients known to be positive for Human immunodeficiency virus infection.
  • Active infectious diseases requiring treatment except for hepatitis B and C.
  • Other malignancies within the last 5 years.
  • History of transplantation (organ, bone marrow transplantation, Peripheral blood stem cell transplantation, etc.).
  • Patients with significant concomitant disease determined by the investigator to be potentially aggravated by the investigational drug.
  • Patients with brain metastases, other central nervous system or other psychiatric disease.
  • Patients who received major surgery, local therapy for HCC, chemotherapy, radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4 weeks prior to Day 1.
  • Patients who received the following treatments within 2 weeks prior to Day 1:

    • Anticoagulations or thrombolytic agents for therapeutic purposes.
    • Systemic anti-viral therapy for hepatitis C/cirrhosis.
    • Blood transfusion
  • History of hypersensitivity to similar agents.
  • Patient is unable to comply with the requirements of the protocol and/or follow-up procedures.
  • IHC confirmed GPC3-negative HCC tumor tissue.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    1

    Drug: GC33

Interventions

  • DrugGC33

    IV administration at 4 escalating dose levels.

06

What researchers measure

Primary outcomes

  1. Determine the safety and tolerability of escalating doses of GC33

    Time frame: Continuously

Secondary outcomes

  1. Characterize the pharmacokinetics of GC33

    Time frame: Continuously

  2. Perform a preliminary assessment of anti-tumor activity of GC33

    Time frame: Continuously

07

Study locations

9 sites
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Karmanos Cancer Center at the Detroit Medical Center
    Detroit, Michigan 48201, United States
  • Washington University
    St. Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Methodist Hospital
    Houston, Texas 77030, United States
  • Swedish Cancer Institute at the Swedish Medical Center
    Seattle, Washington 98104, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Oct 2010 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2008
First posted
Sep 3, 2008
Start
Sep 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2012
Last update
Oct 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00746317
Responsible party
Sponsor
First posted
Sep 3, 2008
Start date
Sep 2008
Primary completion
Oct 2010
Completion
Oct 2012
Last update
Oct 17, 2012

Study contacts

Toshihiko Ohtomo
study chair · Chugai Pharmaceutical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Codrituzumab

Start the discussion